While the epidemic peak of the Ebola crisis slightly begins to wane and with it potential avenues for treatment beginning to emerge, the global health community simply cannot go back to business as usual. »
With this USD 10 million grant from the United States Agency for International Development (USAID) in support of its filarial diseases programme, DNDi targets the development of new oral drugs for human river blindness (onchocerciasis) and elephantiasis (lymphatic filariasis). »
The molecule Emodepside, currently indicated for veterinary usage, will be provided by Bayer to DNDi to support its effort to develop a new oral drug to treat human river blindness. »
The ‘Journal of Biomolecular Screening’ (JBS) released a special edition in collaboration with DNDi on the novel therapeutic approaches for neglected infectious diseases with comprehensive articles in immediate open access.»
DNDi travelled to Colombia to document cutaneous leishmaniasis (CL), which affects about 1 million people every year with disfiguring skin lesions and social stigma. »
Journal of Biomolecular Screening:
Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids»
Malaria Journal:
Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine»
PLOS NTDs:
Strengthening neglected tropical disease research through enhancing research-site capacity: An evaluation of a novel web application to facilitate research collaborations»
